Discussion Forums > Working Towards a Cure
Bluebird Bio Releases Data on Current Gene Therapy Trials
BabyRiya:
Thank you
Canadian_Family:
BlueBird announced its financial results yesterday. Important announcement for us was below:
“In the second half of 2016, we look forward to continued progress on our clinical programs, including initiation of the LentiGlobin HGB-207 Phase 3 study in non-β0/β0 transfusion-dependent thalassemia (TDT), the integration of manufacturing process improvements into our LentiGlobin clinical trials, and presenting updated LentiGlobin clinical data at ASH.”
I only question if they have any success with B0/B0 transfusion dependent thalassemia. I did not see any reference to that in the conference call.
Andy Battaglia:
The beta 0 trials have been split off into their own trials now, with their unique protocol. I don't know if we'll see any updates soon on it. Maybe at ASH in December. My understanding is that the doctors running trials are confident in the eventual success of gene therapy in all forms of thalassemia. My own observation on this process since it began years ago is that there is constant refining and improvement of the vector and the understanding of both dosing and preparation regimen. SK has a new vector that is unique and will give them control over the new genes so they can't get out of control, removing the main concern about gene therapy having any potential dangers. In the long term, it looks quite good.
Canadian_Family:
Thanks Andy.
Appreciate the clarification.
catchR:
Thanks Andy and Canadian Family for the updates...
Navigation
[0] Message Index
[#] Next page
[*] Previous page
Go to full version